-----------------------------------------
OMB Number: 3235-0145
Expires: October 31, 1994
Estimated average burden hours
per response........................14.90
-----------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 3)
SCICLONE PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
80862K 10 4
--------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement [ ]. (A fee
is not required only if the filing person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter disclosure
provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 5 pages.
<PAGE>
<TABLE>
<CAPTION>
<S> <C> <C>
- --------------------------------------- --------------------------------------
CUSIP NO. 80862 10 4 13G Page 2 of 5 Pages
----------
- --------------------------------------- --------------------------------------
- ----------- ---------------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S. S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
THOMAS E. MOORE
###-##-####
- ----------- ---------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
NOT APPLICABLE (a) [ ]
(b) [ ]
- ----------- ---------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ----------- ---------------------------------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
UNITED STATES
- ----------- ---------------------------------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF 3,317,381 (AS OF DECEMBER 31, 1996)
---------- -------------------------------------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY NOT APPLICABLE
---------- -------------------------------------------------------------------------------
BY EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 3,317,381 (AS OF DECEMBER 31, 1996)
---------- -------------------------------------------------------------------------------
WITH 8 SHARED DISPOSITIVE POWER
NOT APPLICABLE
- -------------------------- ---------- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,317,381 (AS OF DECEMBER 31, 1996)
- ----------- ---------------------------------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
- ----------- ---------------------------------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
18.84% (AS OF DECEMBER 31, 1996)
- ----------- ---------------------------------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
IN
- ----------- ---------------------------------------------------------------------------------------------------------
<FN>
*SEE INSTRUCTION BEFORE FILING OUT!
</FN>
</TABLE>
Page 2 of 5 pages
<PAGE>
Schedule 13G
Thomas E. Moore (cont.)
Item 1.
(a) Name of Issuer: SciClone Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices:
901 Mariner's Island Boulevard, Suite 315, San Mateo, CA 94404
Item 2.
(a) Name of Person Filing:
Thomas E. Moore
(b) Address of Principal Business Officer or, if none, Residence:
26201 Dori Lane
Los Altos Hills, CA 94022
(c) Citizenship: United States
(d) Title of Class of Securities: Common Stock
(e) CUSIP Number: 80862K 10 4
Item 3. If this statement is filed pursuant to Rule 13d-1(b),
or 13d-2(b). . .
Not applicable.
Item 4. Ownership
(a) Amount Beneficially Owned:
3,317,381 Common Stock, as of December 31, 1996
(b) Percent of Class: 18.84%, as of December 31, 1996
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 3,317,381
(ii) shared power to vote or to direct the vote: -0-
(iii) sole power to dispose or to direct the disposition
of: 3,317,381
Page 3 of 5 pages.
<PAGE>
Schedule 13G
Thomas E. Moore (cont.)
(iv) shares power to dispose or to direct the disposition
of: -0-
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the Class of
securities, check the following: [ ]
Item 6. Ownership of More than Five Percent of Behalf of Another
Person
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of the Group
Not applicable.
Item 10. Certification
Not applicable.
Page 4 of 5 pages.
<PAGE>
Schedule 13G
Thomas E. Moore (cont.)
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: February 10, 1997
/s/
-----------------------------
THOMAS E. MOORE
Page 5 of 5 pages.
